Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M346Revenue $M20.6Net Margin (%)-134.5Z-Score4.2
Enterprise Value $M298EPS $-0.2Operating Margin %-135.8F-Score4
P/E(ttm))0Cash Flow Per Share $-0.0Pre-tax Margin (%)-135.8Higher ROA y-yY
Price/Book6.710-y EBITDA Growth Rate %-9.2Quick Ratio2.5Cash flow > EarningsY
Price/Sales14.65-y EBITDA Growth Rate %8.0Current Ratio2.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-36.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)7ROE % (ttm)-48.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M132ROI % (ttm)-30.0Gross Margin Increase y-yY

Gurus Latest Trades with ATRS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ATRSJean-Marie Eveillard 2012-06-30 Sold Out $2.63 - $3.3
($3.04)
$ 2.63-14%Sold Out0
ATRSJean-Marie Eveillard 2010-06-30 Buy $1.48 - $1.95
($1.66)
$ 2.6358%New holding, 20000 sh.20,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ATRS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ATRS Jean-Marie Eveillard 2014-09-3020,0000.020
Premium Most recent portfolio changes are included for Premium Members only!


ATRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fickenscher James ESenior Vice President & CFO 2014-12-11Buy40,000$2.55.2view
HOBBS EAMONN PPresident and CEO 2014-09-10Buy9,000$2.219.55view
ROCHE ROBERT P JRDirector 2014-08-13Buy5,000$1.9634.18view
GUETH ANTONDirector 2014-08-11Buy5,000$231.5view
GARRITY THOMAS JDirector 2014-08-11Buy5,000$1.9832.83view
SAMSON MARVINDirector 2014-08-11Buy25,000$231.5view
JACOB LEONARD SDirector 2014-08-11Buy10,000$1.9832.83view
Wotton Paul KPresident and CEO 2014-01-15Sell22,900$5.1-48.43view
JACOB LEONARD SDirector 2014-01-15Sell11,400$5.05-47.92view
APPLE ROBERT FExecutive Vice President & CFO 2014-01-10Sell10,000$5-47.4view

Press Releases about ATRS :

    Quarterly/Annual Reports about ATRS:

    News about ATRS:

    Articles On GuruFocus.com
    Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

    More From Other Websites
    Multiple FDA-Cleared Devices Give This Company Extraordinary Upside Dec 03 2014
    Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
    Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
    Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 01 2014
    Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 01 2014
    Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Other Events Nov 21 2014
    Antares Pharma Appoints James E Fickenscher, Senior Vice President, Chief Financial Officer Nov 18 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Nov 18 2014
    Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer Nov 18 2014
    ANTARES PHARMA, INC. Financials Nov 15 2014
    10-Q for Antares Pharma, Inc. Nov 08 2014
    Antares Pharma posts 3Q loss Nov 06 2014
    Antares Pharma posts 3Q loss Nov 06 2014
    Q3 2014 Antares Pharma Inc Earnings Release - Before Market Open Nov 06 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Nov 06 2014
    Antares Pharma Reports Third Quarter 2014 Operating and Financial Results Nov 06 2014
    Antares Pharma Announces Last Patient Enrolled in Phase 3 Quickshot Study Evaluating... Nov 03 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 03 2014
    Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot® Study Evaluating... Nov 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK